Building on the sumatriptan experience: the development of naratriptan.
Connor
H E
HE
Receptor Pharmacology Unit, GlaxoSmithKline, Stevenage, UK.
D000284:Administration, Oral; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008881:Migraine Disorders / Q000188:drug therapy*; D010880:Piperidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013329:Structure-Activity Relationship; D018170:Sumatriptan / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D016896:Treatment Outcome; D014363:Tryptamines; D014662:Vasoconstrictor Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D007211:Indoles; D010880:Piperidines; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; D014662:Vasoconstrictor Agents; D018170:Sumatriptan; C106783:naratriptan